## Supplementary Table 5. STROBE Statement. Checklist of items that should be included in reports of cohort studies

| Item No | Recommendation | check |
|---------|----------------|-------|
| **Title and abstract** | | |
| 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | ✓ |
| | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | ✓ |
| **Introduction** | | |
| 2 | Explain the scientific background and rationale for the investigation being reported | ✓ |
| **Objectives** | | |
| 3 | State specific objectives, including any prespecified hypotheses | ✓ |
| **Methods** | | |
| 4 | Present key elements of study design early in the paper | ✓ |
| 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | ✓ |
| 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | ✓ |
| | (b) For matched studies, give matching criteria and number of exposed and unexposed | n.a. |
| 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | ✓ |
| 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | ✓ |
| **Bias** | | |
| 9 | Describe any efforts to address potential sources of bias | ✓ |
| **Study size** | | |
| 10 | Explain how the study size was arrived at | ✓ |
| **Quantitative variables** | | |
| 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | ✓ |
| **Statistical methods** | | |
| 12 | (a) Describe all statistical methods, including those used to control for confounding | ✓ |
| | (b) Describe any methods used to examine subgroups and interactions | ✓ |
| | (c) Explain how missing data were addressed | ✓ |
| | (d) If applicable, explain how loss to follow-up was addressed | ✓ |
| | (e) Describe any sensitivity analyses | n.a. |
| **Results** | | |
| 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | ✓ |
| | (b) Give reasons for non-participation at each stage | n.a. (parents could stop participation without giving a reason at any time) |
| | (c) Consider use of a flow diagram | n.a. |
| 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | ✓ |
| | (b) Indicate number of participants with missing data for each variable of interest | ✓ (data incorporated) |
| **Outcome data** | 15* | Report numbers of outcome events or summary measures over time | n.a. |
|------------------|-----|-------------------------------------------------------------|-----|
| **Main results** | 16  | *(a)* Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | n.a. |
|                  |     | *(b)* Report category boundaries when continuous variables were categorized | √  |
|                  |     | *(c)* If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | n.a. |
| **Other analyses** | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | √  |

**Discussion**

| **Key results** | 18  | Summarise key results with reference to study objectives | √  |
|-----------------|-----|---------------------------------------------------------|-----|
| **Limitations** | 19  | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | √  |
| **Interpretation** | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | √  |
| **Generalisability** | 21  | Discuss the generalisability (external validity) of the study results | √  |

**Other information**

| **Funding** | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | √  |

*Give information separately for exposed and unexposed groups.*